1642 related articles for article (PubMed ID: 31780379)
21. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
22. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Nagaraj G; Ma CX
Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
[TBL] [Abstract][Full Text] [Related]
23. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
24. Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.
Fuentes-Antrás J; Martínez-Rodríguez A; Guevara-Hoyer K; López-Cade I; Lorca V; Pascual A; de Luna A; Ramírez-Ruda C; Swindell J; Flores P; Lluch A; Cescon DW; Pérez-Segura P; Ocaña A; Jones F; Moreno F; García-Barberán V; García-Sáenz JÁ
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511178
[TBL] [Abstract][Full Text] [Related]
25. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
27. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.
Cetin B; Wabl CA; Gumusay O
Future Oncol; 2022 Mar; 18(9):1143-1157. PubMed ID: 35137602
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
29. Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.
Goetz MP; Hamilton EP; Campone M; Hurvitz SA; Cortes J; Johnston S; Llombart-Cussac A; Kaufman PA; Toi M; Jerusalem G; Graham H; Wang H; Jansen VM; Litchfield LM; Martin M
Clin Cancer Res; 2024 May; 30(10):2233-2244. PubMed ID: 37889120
[TBL] [Abstract][Full Text] [Related]
30. CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.
Migliaccio I; Bonechi M; McCartney A; Guarducci C; Benelli M; Biganzoli L; Di Leo A; Malorni L
Cancer Treat Rev; 2021 Feb; 93():102136. PubMed ID: 33360919
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
O'Sullivan CC; Clarke R; Goetz MP; Robertson J
JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
[TBL] [Abstract][Full Text] [Related]
32. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
[TBL] [Abstract][Full Text] [Related]
33. CDK4/6 Inhibitor Efficacy in
Lloyd MR; Brett JO; Carmeli A; Weipert CM; Zhang N; Yu J; Bucheit L; Medford AJ; Wagle N; Bardia A; Wander SA
NEJM Evid; 2024 May; 3(5):EVIDoa2300231. PubMed ID: 38815172
[TBL] [Abstract][Full Text] [Related]
34. The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Lawson M; Cureton N; Ros S; Cheraghchi-Bashi A; Urosevic J; D'Arcy S; Delpuech O; DuPont M; Fisher DI; Gangl ET; Lewis H; Trueman D; Wali N; Williamson SC; Moss J; Montaudon E; Derrien H; Marangoni E; Miragaia RJ; Gagrica S; Morentin-Gutierrez P; Moss TA; Maglennon G; Sutton D; Polanski R; Rosen A; Cairns J; Zhang P; Sánchez-Guixé M; Serra V; Critchlow SE; Scott JS; Lindemann JPO; Barry ST; Klinowska T; Morrow CJ; Carnevalli LS
Cancer Res; 2023 Dec; 83(23):3989-4004. PubMed ID: 37725704
[TBL] [Abstract][Full Text] [Related]
35. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
36. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ
Nat Commun; 2021 Aug; 12(1):5112. PubMed ID: 34433817
[TBL] [Abstract][Full Text] [Related]
37. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
38. Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer.
Bayraktar S; Batoo S; Al-Hattab E; Basu S; Okuno S; Glück S
Future Oncol; 2020 Nov; 16(32):2661-2672. PubMed ID: 32805138
[TBL] [Abstract][Full Text] [Related]
39. Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.
Fontanella C; Giorgi CA; Russo S; Angelini S; Nicolardi L; Giarratano T; Frezzini S; Pestrin M; Palleschi D; Bolzonello S; Parolin V; Haspinger ER; De Rossi C; Greco F; Gerratana L
Crit Rev Oncol Hematol; 2022 Dec; 180():103848. PubMed ID: 36257536
[TBL] [Abstract][Full Text] [Related]
40. Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.
Davis AA; Luo J; Zheng T; Dai C; Dong X; Tan L; Suresh R; Ademuyiwa FO; Rigden C; Rearden TP; Clifton K; Weilbaecher K; Frith A; Tandra PK; Summa T; Haas B; Thomas S; Hernandez-Aya LF; Peterson LL; Wang X; Luo SJ; Zhou K; Du P; Jia S; King BL; Krishnamurthy J; Ma CX
Clin Cancer Res; 2023 May; 29(9):1719-1729. PubMed ID: 36693175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]